215 results about "Gamma-Linolenic acid" patented technology

A nutrition bar comprising about 10% wt or more of soy and / or rice protein, at least one transition metal or transition metal compound, and about 2% wt or more of a humectant, and wherein the at least one transition metal or transition metal compound is in a substantially water insoluble form at 20° C. or the nutrition bar has an Aw of 0.45 or less or about 1% wt or more of the soy and / or rice protein is in the form of nuggets and the humectant is selected from polyols. The bars have elevated levels of soy and / or rice protein, yet do not suffer unacceptable from a deterioration in taste or other organoleptic properties over time. In other aspects, a nutrition bar or other food which incorporates pro-oxidants and / or polyunsaturated fatty acids or their sources in encapsulated form, especially as microcapsules. The pro-oxidants may be metal salts such as copper, manganese, iron and / or zinc salts. Sources of omega-3 fatty acids include fish oil. Processes for preparing the polyunsaturated fatty acid capsules are also disclosed. The polyunsaturated fatty acid capsules / microcapsules are prepared by forming an emulsion of the unsaturated fatty acid with a carrier, spray drying the emulsion to form a powder and encapsulating powder, especially with a fluid bed. The invention is especially useful for encapsulating polyunsaturated fatty acids, or oil sources thereof, most preferably omega-3 and omega-6 fatty acids, such as arachidonic acid, docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), lineoleic acid, linolenic acid (alpha linolenic acid), and gamma-linolenic acids, fish oil, and oil sources of C18:2 and C18:3 fatty acids such as canola oil, soybean oil or blends thereof.

The subject invention relates to the identification of several genes involved in the elongation of polyunsaturated acids (i.e., "elongases") and to uses thereof. At least two of these genes are also involved in the elongation of monounsaturated fatty acids. In particular, elongase is utilized in the conversion of gamma linolenic acid (GLA) to dihomogamma linolenic acid (DGLA) and in the conversion of AA to adrenic acid (ADA), or eicosapentaenoic acid (EPA) to omega3-docosapentaenoic acid (DPA). DGLA may be utilized in the production of polyunsaturated fatty acids, such as arachidonic acid (AA), docosahexaenoic acid (DHA), EPA, adrenic acid, omega6-docosapentaenoic acid or omega3-docosapentaenoic acid which may be added to pharmaceutical compositions, nutritional compositions, animal feeds, as well as other products such as cosmetics.

This invention is directed to a dietary regimen and a unique combination of nutritional supplements and a method. More specifically, this invention is directed to a unique combination of nutritional supplements which provides symptomatic relief from arthritis. The unique combination of nutritional supplements of this invention is believed to function by both increasing the available (effective blood level) of anti-inflammatory agents and promotion of the healing / regenerative process in the effected joints, thus, producing unexpected and lasting symptomatic relief from the debilitating effects of both osteoarthritis and rheumatoid arthritis. The essential nutritional supplements of the dietary regimen of this invention are as follows: (a) gamma linolenic acid (unrefined), hereinafter "GLA"(b) a mixture of eicosapentaenoic acid and docosahexaneoic acid, hereinafter collectively "EPA"(c) a mixture of chondroitin sulfate, N-acetyl glucosamine sulfate, glucosamine sulfate and manganese aspartate, hereinafter collectively "CHONDROX"The regimen is adjusted based upon the weight of the individual, and once symptomatic relief is achieved, the individual remains essentially free from the debilitating effects of arthritis so as long the daily regimen is faithfully followed.

Disclosed herein are alternative, enhanced, and cheaper methods of improving cognitive functions in a subject using a lipid composition conjugated with omega-3 and omega-6 fatty acids, with specific amounts and specific conjugation patterns of LA, linolenic acid (alpha-linolenic acid, gamma-linolenic acid) DHA and eicosapentaenoyl (EPA), e.g. utilizing different sources of lipids.Disclosed herein is a lipid preparation, said preparation comprising a phosphatidylserine moiety, and poly-unsaturated fatty acid (PUFA) acyl groups, particularly long-chain poly-unsaturated fatty acid (LC-PUFA) acyl groups such as omega-3 and / or omega-6 acyl groups, wherein said PUFA is covalently bound to said glycerophospholipid. Said lipid preparations are particularly useful in the treatment of mental and cognitive disorders, e.g. ADHD (attention deficit hyperactivity disorder) and Alzheimer's disease.The disclosed preparations present improved bioactivity, and are useful in the treatment of various cognitive and mental conditions and disorders, as well as for maintenance of normal functions of brain-related systems and processes.

The subject invention relates to the identification of four genes involved in the elongation of polyunsaturated acids (i.e., “elongases”) and to uses thereof. Two of these genes are also involved in the elongation of monounsaturated fatty acids. In particular, elongase is utilized in the conversion of gamma linolenic acid (GLA) to dihomogamma linolenic acid (DGLA) and in the conversion of DGLA or 20:4n-3 to eicosapentaenoic acid (EPA). DGLA may be utilized in the production of polyunsaturated fatty acids, such as arachidonic acid (AA), docosahexaenoic acid (DHA), EPA, adrenic acid, ω6-docosapentaenoic acid or ω3-docosapentaenoic acid which may be added to pharmaceutical compositions, nutritional compositions, animal feeds, as well as other products such as cosmetics.

The subject invention relates to the identification of several genes involved in the elongation of polyunsaturated acids (i.e., "elongases") and to uses thereof. At least two of these genes are also involved in the elongation of monounsaturated fatty acids. In particular, elongase is utilized in the conversion of gamma linolenic acid (GLA) to dihomogamma linolenic acid (DGLA) and in the conversion of AA to adrenic acid (ADA), or eicosapentaenoic acid (EPA) to omega3-docosapentaenoic acid (DPA). DGLA may be utilized in the production of polyunsaturated fatty acids, such as arachidonic acid (AA), docosahexaenoic acid (DHA), EPA, adrenic acid, omega6-docosapentaenoic acid or omega3-docosapentaenoic acid which may be added to pharmaceutical compositions, nutritional compositions, animal feeds, as well as other products such as cosmetics.

The subject invention relates to the identification of several genes involved in the elongation of polyunsaturated acids (i.e., “elongases”) and to uses thereof. At least two of these genes are also involved in the elongation of monounsaturated fatty acids. In particular, elongase is utilized in the conversion of gamma linolenic acid (GLA) to dihomogama linolenic acid (DGLA) and in the conversion of DGLA or 20:4n-3 to eicosapentaenoic acid (EPA). DGLA may be utilized in the production of polyunsaturated fatty acids, such as arachiodonic acid (AA), docosahexaenoic acid (DHA), EPA, adrenic acid, ω6-docosapentaenoic acid or ω3-docosapentaenoic acid which may be added to pharmaceutical compositions, nutritional compositions, animal feeds, as well as other products such as cosmetics.

The present invention relates to methods for the production of γ-linolenic acid (GLA) in oleaginous yeast. Thus, Δ12 and Δ6 desaturases able to catalyze the conversion of oleic acid to GLA have been introduced into the genome of Yarrowia, using zeta-directed integration. Transformed strains produced over 25% GLA in the total lipids, as opposed to wildtype Yarrowia that is unable to synthesize any GLA. Metabolic engineering and fermentation methods are provided to further enhance GLA productivity in oleaginous yeast.

The production and use, and in particular, the extraction, separation, synthesis and recovery of polar lipid-rich fractions containing gamma linolenic acid (GLA) and / or stearidonic acid (SDA) from seeds and microorganisms and their use in human food applications, animal feed, pharmaceuticals and cosmetics.

The present invention provides a composition, such as a food and pharmaceutical agent, which comprises dihomo-γ-linolenic acid, and which has the effect of preventing or treating skin diseases; a composition such as a food and pharmaceutical agent which comprises dihomo-γ-linolenic acid and which has the effect of preventing or treating skin diseases; and a composition which comprises dihomo-γ-linolenic acid and which has the effect of preventing or treating diseases related to increased mast cell count.

Embodiments of the present invention provide improved aquaculture products and methods of producing such aquaculture products by incorporating healthier lipids containing stearidonic acid and gamma linolenic acid into the aquaculture feed. This in turn improves the health profile of the aquatic animals promoting growth and limiting commercial losses. Furthermore, embodiments of the present invention provide methods for producing said products. In one embodiment of the invention, an aquaculture animal may be fed a feed comprising a transgenic plant product. In other embodiments of the invention, cold water fish meat, warm water fish meat, and crustacean meat products comprising SDA, GLA, EPA, and DHA are disclosed. In further embodiments of the invention, other aquaculture feed products comprising SDA, and GLA are disclosed.

A dietary supplement system includes a dietary supplement composition for oral administration by an individual in the morning, the composition, including (a) a telomere maintenance complex including: Purslane extract (aerial parts); Turmeric rhizome extract (95% curcuminoids); Quercetin dehydrate, Cayenne pepper fruit; Vanadium (as vanadyl sulfate); Fenugreek seed; Astragalus root extract, Omega fatty acid complex including linoleic acid; alpha-linolenic acid; oleic acid borage seed oil gamma-linolenic acid), evening primrose oil fish body oil (eicosapentaenoic acid; docosahexaenoic acid); (b) a calorie restriction mimetics and gene expression complex including Trans-resveratrol (from Polygonum cuspidatum root extract); Pterostilbene Fisetin 50% (Buxus microphlla Sieb (stem and leaf; Alpha lipoic acid, Coenzyme Q-10, Betaine HCl, Sulfur (from methylsulfonylmethane); L-Carnitine tartrate; L-Carnitine HCl, and (c) a free radical scavenger complex, including Green tea leaf extract catechin and polyphenols); Anthocyanins (from bilberry fruit and grape skin extracts).

The present disclosure relates to novel nutritional and cosmeceutical compositions comprising an oil extracted from the seeds of Boraginaceae, particularly Buglossoides arvensis, in the range of from 1 to 100% by weight of the total composition. The oil has particular advantages over oils extracted from other seeds in that the oil is comprised of from 14% to at least 17% stearidonic acid and less than 7% gamma-linolenic acid. The oil composition is particularly suited for oral or topical administration and for dietary, cosmetic, pharmaceutical and healthcare uses.

The invention relates to a preparation method for tea oil by double helix low-temperature squeezing, which comprises the following steps: a) drying at low temperature; drying screened tea seeds by a flat dryer and an induced fan, wherein the drying temperature is 45-55 degree C, the drying time is 55-65 minutes, and the moisture content of dried tea seed is 6-10%; b) husking for separation; c) squeezing at low temperature; d) making squeezed oil stand for filtration; e) performing winterization treatment; and f) obtaining the finished product. Through low-temperature drying, squeezing by a double helix squeezer as well as the filtration technology by standing, the preparation method disclosed by the invention can avoid overheating and excessive chemical treatment to the oil, avoid residues of harmful substances generated during high-temperature processing, and avoid residues of acid, alkali and heavy metals due to addition of chemical addition agents; in addition, the technology disclosed by the invention can retain the pure natural quality of the tea-seed oil, and as much as possible retains physiological characteristic substances in the tea oil, such as vitamin E, gamma-linolenic acid and other beneficial components.

The present invention relates to methods for the production of γ-linolenic acid (GLA) in oleaginous yeast. Thus, Δ12 and Δ6 desaturases able to catalyze the conversion of oleic acid to GLA have been introduced into the genome of Yarrowia, using zeta-directed integration. Transformed strains produced over 25% GLA in the total lipids, as opposed to wildtype Yarrowia that is unable to synthesize any GLA. Metabolic engineering and fermentation methods are provided to further enhance GLA productivity in oleaginous yeast.

A nutrition bar or other food which incorporates pro-oxidants and / or polyunsaturated fatty acids or their sources in encapsulated form, especially as microcapsules. The pro-oxidants may be metal salts such as copper, manganese, iron and / or zinc salts. Sources of omega-3 fatty acids include fish oil. Processes for preparing the polyunsaturated fatty acid capsules are also disclosed. The polyunsaturated fatty acid capsules / microcapsules are prepared by forming an emulsion of the unsaturated fatty acid with a carrier, spray drying the emulsion to form a powder and encapsulating powder, especially with a fluid bed. The invention is especially useful for encapsulating polyunsaturated fatty acids, or oil sources thereof, most preferably omega-3 and omega-6 fatty acids, such as arachidonic acid, docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), lineoleic acid, linolenic acid (alpha linolenic acid), and gamma-linolenic acids, fish oil, and oil sources of C18:2 and C18:3 fatty acids such as canola oil, soybean oil or blends thereof.

A process for increasing the concentration of PUFA triglycerides present in natural PUFA oils, in which a natural PUFA oil having a triglyceride content of more than 85% by weight, based on the total weight of the mixture, and having a total PUFA content of more than 39% by weight of total fatty acids is dissolved in an organic solvent or an organic solvent mixture, the mixture is allowed to stand at a temperature of from −35° C. to −100° C. for a period of more than five minutes, the mixture is separated into a supernatant comprising PUFA-triglyceride mixture and a sediment phase, the separation preferably taking place by filtration or centrifugation, and the solvent or solvent mixture, after the removal of the sediment phase, is separated from the supernatant. PUFA-triglyceride mixtures having a PUFA content of more than 55% by weight of total fatty acids of a main PUFA, or at least two PUFAs selected from stearidonic acid, eicosapentaenoic acid, docosapentaenoic acid, docosahexaenoic acid, gamma-linolenic acid and arachidonic acid, and also use thereof in pharmaceutical, cosmetics and food preparations.

Compositions for the treatment of symptoms of inflammatory disorders may include gamma-linolenic acid or dihomogammalinolenic acid, an inhibitor of Δ5 desaturase, and optionally stearidonic acid or ω-3 arachidonic acid. Preferred formulations may be in the form of a good tasting, preferably milk or fruit based drink, or a dried powder. Compositions reduce inflammation and inhibit increase in serum arachidonic acid associated with gamma-linolenic acid.

An instant naked oats powder as solid beverage for the patients of hyperlipomia and diabetes is prepared from naked oats through removing impurities and fine fibres, soaking in hot water, grinding, adding alpha-amylase, auxiliary materials and emulsifier, homogenizing, emulsifying, and spray drying. Its advantages are high dissolving speed and solubility (more than 89.44%), and rich gamma-linolenic acid.

The invention relates to a fatty acid component microcapsule and a preparation method thereof, and belongs to the field of food and medicine. The microcapsule consists of crude oil containing fatty acids and auxiliary materials, wherein the auxiliary materials consist of wall materials, an antioxidant and an emulsifier. The microcapsule consists of the following ingredients by weight: 30-50% of the crude oil, 34-60% of the wall materials, 2-10% of the antioxidant and 6% of the emulsifier. According to the fatty acid component microcapsule and the preparation method thereof, the microcapsule with excellent water-solubility is prepared from palmitic acid (PA), oleic acid (OA), linoleic acid (LA), alpha-linolenic acid, eicosapentaenoic acid (EPA) and docosahexenoic acid (DHA). The microcapsule can be directly taken with water and can also be used for clinical patients in nasal feeding and tube feeding to improve biological digestibility, absorptivity and biopotency.

The invention discloses a method for extracting boxthorn seed oil by supercritical CO2. The method comprises the following steps: a, drying and grinding boxthorn seeds and loading in extraction kettle; b, injecting the supercritical CO2 into the extraction kettle, and extracting under the temperature of 40-50 degrees centigrade, pressure of 30-40Mpa and CO2 flow rate of 8-18L / min for 2.5-4 hours; c, inducing the CO2 fluid solved with boxthorn seed oil into a separation kettle, separating out the boxthorn seed oil by adjusting temperature and pressure, compressing the CO2 gas and inducing into the extraction kettle for circulation. The invention has a simple process and convenient operation, avoids the organic solvent residue, shortens the extraction time, increases the boxthorn seed oil extraction efficiency, especially increases the contents of alpha-linolenic acid and gamma-linolenic acid in the boxthorn seed oil greatly.

The invention relates to fatty acid component balanced children type nutrition blended oil containing multiple active ingredients. The nutrition blended oil prepared from a plurality kinds of vegetable oils contains omega-6 polyunsaturated fatty acid (PUFA), and omega-3 PUFA, so that when the blended oil eaten by children and the fat of other dietary sources are comprehensive evaluated, the ratio of omega-6 to omega-3 is (4-6):1, and the recommended value of Chinese Nutrition Society is met. The nutrition blended oil contains 2 percent of gamma-linolenic acid, and the content sum of lauric acid, myristic acid and palmitic acid is less than 4.5 percent. In addition, the nutrition blended oil also contains multiple active ingredients without antioxidants. The nutrition blended oil has the advantages of contributing to improvement on body constitution and intelligence of users, preventing the occurrence of cardiovascular and cerebrovascular diseases, reducing the occurrence of obesity, hyperlipidemia and thrombosis, and the like caused by fat nutrition unbalance, along with low cost, balanced fatty acid nutrition, multiple active ingredients and higher safety.

The invention discloses a mixed grease composition suitable for being added into infant formula food and a preparation method and an application thereof. The species of fatty acids and the mixture ratio thereof in the mixed grease composition approach the level of breast milk, the mixed grease composition contains oleic acid, palmitic acid, linoleic acid and linolenic acid, wherein gamma-linolenic acid accounts for 0.23%-1.14% of the total weight of the mixed grease composition. The content of the fatty acids and the mixture ratio thereof of mixed grease are very close to the average level of the breast milk, the content of the gamma-linolenic acid is further strengthened and the mixed grease composition can be directly used in preparation of the infant formula food, thereby overcoming the problem that the content of the gamma-linolenic acid in the existing infant formula food is low, enabling the fat composition in the infant formula food to be more reasonable and closer to the breast milk, simultaneously simplifying the processing procedure of the infant formula food and improving the product quality.

Linoleic acid is converted into γ-linolenic acid by the enzyme Δ6-desaturase. The present invention is directed to isolated nucleic acids comprising the Δ6-desaturase gene. More particularly, the isolated nucleic acid comprises the promoter, coding region and termination regions of the Δ6-desaturase gene. The present invention provides recombinant constructions comprising the Δ6-desaturase coding region in functional combination with heterologous regulatory sequences. The nucleic acids and recombinant constructions of the instant invention are useful in the production of GLA in transgenic organisms.

A method for producing gamma-linolenic acid oil by microbial fermentation comprises the following process steps: culturing high-level expression strains of malic enzyme and gamma-linolenic acid synthetase; performing activation and amplification culture on original strains; then performing primary fermentation, secondary fermentation, third-stage fermentation and a fourth-stage fermentation; dehydrating, drying and extracting the oil. The method has the advantages of good strains, high yield, high dry bacteria yield up to 10-30%, good oil yield up to 35-55%, satisfactory gamma-linolenic acid yield up to 18-29% and low production cost. The method can help reduce the cost of raw materials for the production process by 50-70%. The semi-continuous fermentation or continuous fermentation process is advanced, scientific and mature, can be used for large scale industrialized production, and achieve 50-500t fourth-stage fermentation level.

Compositions, dietary supplements and medical foods for the treatment of symptoms of inflammatory disorders may include gamma-linolenic acid or dihomogammalinolenic acid, an inhibitor of Δ5 desaturase, and optionally stearidonic acid or ω−3 arachidonic acid. Preferred formulations may be in the form of a good tasting, preferably milk or fruit based drink, or a dried powder. Compositions reduce inflammation and inhibit increase in serum arachidonic acid associated with gamma-linolenic acid. The compositions of the invention may also be used for the treatment of cytokine mediated disorders in patients in need thereof.

The subject invention relates to the identification of a gene involved in the elongation of polyunsaturated fatty acids containing unsaturation at the carbon 9 position (i.e., “Δ9-elongase”) and to uses thereof. In particular, Δ9-elongase may be utilized, for example, in the conversion of linoleic acid (LA, 18:2n-6) to eicosadienoic acid (EDA, 20:2n-6). The production of dihomo-γ-linolenic acid (DGLA, 20:3n-6) from eicosadienoic acid (EDA, 20:2n-6), and arachidonic acid (AA, 20:4n-6) from dihomo-γ-linolenic acid (DGLA, 20:3n-6) is then catalyzed by Δ8-desaturase and Δ5-desaturase, respectively. AA or polyunsaturated fatty acids produced therefrom may be added to pharmaceutical compositions, nutritional compositions, animal feeds, as well as other products such as cosmetics.

The present invention relates to the production of γ-linolenic acid (18:3Δ6,9,12) or stearidonic acid (18:4Δ6,9,12,15) or γ-linolenic acid (18:3Δ6,9,12) and stearidonic acid (18:4Δ6,9,12,15) in transgenic plants of the family Brassicaceae, where the transgenic plants comprise at least 10% by weight of oleic acid based on the total fatty acid content and, as the result of the activity of the Δ6-desaturases used in the method, have an increased Δ6-C18-fatty acid content. The invention furthermore relates to novel nucleic acid sequences which code for the Δ6-desaturases used in the method, gene constructs comprising these nucleic acid sequences, a vector and transgenic plants comprising at least one nucleic acid sequence or a gene construct.

The present invention relates to compositions and methods for preparing polyunsaturated long chain fatty acids in plants, plant parts and plant cells, such as leaves, roots, fruits and seeds. Nucleic acid sequences and constructs encoding fatty acid desaturases, including Δ5-desaturases, Δ6-desaturases and Δ12-desaturases, are used to generate transgenic plants, plant parts and cells which contain and express one or more transgenes encoding one or more desaturases. Expression of the desaturases with different substrate specificities in the plant system permit the large scale production of polyunsaturated long chain fatty acids such as docosahexaenoic acid, eicosapentaenoic acid, α-linolenic acid, gamma-linolenic acid, arachidonic acid and the like for modification of the fatty acid profile of plants, plant parts and tissues. Manipulation of the fatty acid profiles allows for the production of commercial quantities of novel plant oils and products.